Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Two Way Cross Over BE Fasting Pilot Study of Ropinirole Hydrochloride CR 2mg Tablets

This study has been completed.
Information provided by (Responsible Party):
Lupin Ltd. Identifier:
First received: October 19, 2012
Last updated: October 22, 2012
Last verified: October 2012

Study subjects were screened and enrolled for the study. Subjects were housed in the clinical facility from not less than 12 hours pre-dose till at least 24 hours post-dose in each period. After maintaining at least 10 hours of overnight fast Test or Reference product was administered orally (as per the randomization schedule) to each subject with about 240 mL of water at ambient temperature in each period by trained study personnel.

The pre-dose (0.00 hours) blood sample was collected before dosing and post-dose samples were collected at 2.00, 3.00, 4.00, 5.00, 5.50, 6.00, 6.50, 7.00, 7.50, 8.00, 8.50, 9.00, 9.50, 10.00, 10.50, 11.00, 12.00, 14.00, 16.00, 20.00, 24.00 and 30.00 hours in each study period with a washout period of 7 days between the dosing of two periods. Subjects were continuously monitored for well being i.e., blood pressure, radial pulse and oral temperature before check-in, prior to drug administration and at regular intervals post dose in each period. The concentration of Ropinirole in plasma samples obtained from study subjects was determined using validated LC-MS/MS method. Pharmacokinetic and statistical analyses were performed on obtained drug concentration data, using appropriate software.

Condition Intervention Phase
Pharmacokinetic Study
Drug: Test Product (Ropinirole)
Drug: Reference Product (REQUIP )
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label

Resource links provided by NLM:

Further study details as provided by Lupin Ltd.:

Primary Outcome Measures:
  • Description of the pharmacokinetic (PK) profile for Ropinirole in terms of maximum observed plasma concentration (Cmax) and area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC) for each treatment period. [ Time Frame: Predose, 2.00, 3.00, 4.00, 5.00, 5.50, 6.00, 6.50, 7.00, 7.50, 8.00, 8.50, 9.00, 9.50, 10.00, 10.50, 11.00, 12.00, 14.00, 16.00, 20.00, 24.00 and 30.00 hours ]

Secondary Outcome Measures:
  • Description of the safety profile in terms of adverse events, clinical laboratory assessments , vital signs (blood pressure and pulse rate), physical examinations and electrocardiograms [ Time Frame: From baseline day 0 through to post study Follow-up (maximum 20 days) ]

Enrollment: 12
Study Start Date: September 2008
Study Completion Date: October 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Test Product
Drug: Ropinirole Single oral dose of Ropinirole hydrochloride CR 2mg Tablets under fasting conditions
Drug: Test Product (Ropinirole)
one Tablet at "0" hour
Other Name: Ropinirole HCl Tablets CR 2mg
Drug: Reference Product (REQUIP )
one Tablet at "0" hour
Other Name: REQUIP XL Tablets
Experimental: Reference Product
Drug: Ropinirole REQUIP XL Tablets (Ropinirole hydrochloride CR 2mg)commercial formulation under fasting conditions
Drug: Test Product (Ropinirole)
one Tablet at "0" hour
Other Name: Ropinirole HCl Tablets CR 2mg
Drug: Reference Product (REQUIP )
one Tablet at "0" hour
Other Name: REQUIP XL Tablets


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

i. Availability of volunteer for the entire study period and willingness to adhere to protocol requirements as evidenced by the written informed consent form (ICF) duly signed by the volunteer.

ii. Healthy human male subjects between 18-45 years Weighing at least 50 kg and with a body mass index (BMI) of 18 kg/m2 and less than or equal to 25 kg/m2 (according to the formula of BMI = weight (kg)/[height (m)]2).

iii. Subjects who have no evidence of underlying disease during screening medical history and whose physical examination is performed within 14 days prior to commencement of the study.

iv. Subjects whose screening laboratory values are within normal limits or considered by the physician/Principal Investigator to be of no clinical significance.

v. Light-, non- or ex-smokers. Light smokers are defined as someone smoking 10 cigarettes or less per day, and ex-smokers are defined as someone who completely stopped smoking for at least 3 months.

Exclusion Criteria:

History or presence of significant:

I. History of hypersensitivity or idiosyncratic reactions to Ropinirole or any related products.

II. Cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease.

III. Alcohol dependence, alcohol abuse or drug abuse within past one year. IV. Moderate to heavy smoking (>10 cigarettes/day) or consumption of tobacco products.

V. History of difficulty in swallowing VI. Clinically significant illness within 4 weeks before the start of the study VII. Asthma, urticaria or other allergic type reactions after taking any medication.

Blood loss/donation of more than 350 mL within 3 months prior to study dosing or difficulty in donating blood.

Participation in another clinical study not involving donation of blood, within the preceding 90 days of study start.

Subjects who have:

i. Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg

ii. Diastolic blood pressure less than 60 mm of Hg or more than 94 mm of Hg. Minor deviations (1-3 mm Hg) at check-in may be acceptable at the discretion of the physician /investigator.

iii. Pulse rate below 50/min. or above 105/min.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01712568

Sipra Labs Limited
Hyderabad, Andhra Pradesh, India, 500 038
Sponsors and Collaborators
Lupin Ltd.
Principal Investigator: Satyanarayana V, M.Pharma., Ph.D Sipra Labs Limited
  More Information

Responsible Party: Lupin Ltd. Identifier: NCT01712568     History of Changes
Other Study ID Numbers: SLL/RPR/1117/08
Study First Received: October 19, 2012
Last Updated: October 22, 2012

Additional relevant MeSH terms:
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on May 22, 2017